What is Modulight Bio?
Modulight Bio is a pioneering biotechnology enterprise dedicated to the development of a precision neuromodulation platform. By utilizing optogenetics, the company aims to provide targeted, fast-acting relief for patients suffering from severe neurological disorders, including seizures, tremors, and chronic neuropathic pain. The company's current operational focus is centered on advancing its lead candidate for trigeminal neuropathic pain into clinical studies. Through the integration of light-based technology and neurobiology, Modulight Bio is working to redefine the standard of care for patients who have historically faced limited or ineffective treatment options. Their market position is defined by a commitment to rigorous scientific validation and the pursuit of transformative therapeutic outcomes.
How much funding has Modulight Bio raised?
Modulight Bio has raised a total of $12.2M across 1 funding round:
Seed
$12.2M
Seed (2025): $12.2M with participation from Sara Capital, LocalGlobe, SilverArc Capital, Jibe Ventures, and Secret Chord Ventures
Key Investors in Modulight Bio
Jibe Ventures
Jibe Ventures is an early-stage venture capital fund based in Israel, focusing on seed and pre-seed investments. The firm aims to foster genuine connections with founders, assisting them in various aspects such as team building, ideation, and go-to-market strategies.
Secret Chord Ventures
Secret Chord Ventures is an Israel-based early-stage venture firm that invests in exceptional entrepreneurs aiming to create category-defining companies. The firm focuses on pre-seed and seed investments, fostering close relationships with founders as trusted advisors.
SilverArc Capital
SilverArc Capital is an investment management firm that specializes in the healthcare sector. The company focuses on providing investment solutions tailored to the unique needs of healthcare clients, aiming to deliver value and expertise to those looking to invest in the industry.
What's next for Modulight Bio?
With the recent capital infusion, Modulight Bio is well-positioned to accelerate its clinical trial roadmap and expand its research capabilities. The strategic allocation of these funds will likely prioritize the advancement of its lead indication, trigeminal neuropathic pain, through the regulatory approval process. Furthermore, the company is expected to scale its internal R&D infrastructure to explore additional neurological applications for its optogenetics platform. As the firm moves into this next phase of growth, the focus will remain on achieving key clinical milestones that demonstrate both the safety and efficacy of its technology. Investors and industry observers will be closely monitoring the company's progress as it seeks to translate its innovative research into a viable, market-ready therapeutic solution.
See full Modulight Bio company page
